

Ruth L Coleman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4882637/publications.pdf>

Version: 2024-02-01

30
papers

2,292
citations

471371

17
h-index

477173

29
g-index

32
all docs

32
docs citations

32
times ranked

3774
citing authors

#	ARTICLE	IF	CITATIONS
1	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. <i>Nature Genetics</i> , 2011, 43, 117-120.	9.4	390
2	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 431-437.	5.5	379
3	Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes: UKPDS 66. <i>Diabetes Care</i> , 2004, 27, 201-207.	4.3	254
4	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 877-886.	5.5	245
5	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016, 48, 1055-1059.	9.4	165
6	Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1292-1293.	4.3	158
7	Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort. <i>Diabetes Care</i> , 2009, 32, 708-713.	4.3	125
8	Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus. <i>Circulation</i> , 2013, 127, 980-987.	1.6	99
9	Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. <i>Diabetes Care</i> , 2021, 44, 2231-2237.	4.3	51
10	Non-HDL Cholesterol Is Less Informative Than the Total-to-HDL Cholesterol Ratio in Predicting Cardiovascular Risk in Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 1796-1797.	4.3	48
11	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. <i>Annals of Internal Medicine</i> , 2021, 174, 58-68.	2.0	47
12	Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 206-215.	5.5	36
13	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. <i>Diabetes Care</i> , 2020, 43, 2493-2499.	4.3	29
14	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021, 44, 1877-1884.	4.3	25
15	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021, 44, 2673-2682.	4.3	23
16	Design and rationale of the EMPAâ€¦VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2580-2590.	1.4	18
17	Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. <i>Cardiovascular Diabetology</i> , 2019, 18, 135.	2.7	17
18	Evaluation of a Self-Administered Oral Glucose Tolerance Test. <i>Diabetes Care</i> , 2013, 36, 1483-1488.	4.3	14

#	ARTICLE	IF	CITATIONS
19	Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials. <i>Diabetologia</i> , 2020, 63, 2482-2485.	2.9	14
20	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. <i>Diabetes Care</i> , 2020, 43, 2242-2247.	4.3	11
21	Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1151-1156.	2.2	8
22	Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2022, 45, e1-e2.	4.3	6
23	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108488.	1.1	4
24	Health selection into neighborhoods among patients enrolled in a clinical trial. <i>Preventive Medicine Reports</i> , 2017, 8, 51-54.	0.8	3
25	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 69-74.	1.2	3
26	Refeeding risks in patients requiring intravenous nutrition support: Results of a two-centre, prospective, double-blind, randomised controlled trial. <i>Clinical Nutrition ESPEN</i> , 2021, 41, 143-152.	0.5	3
27	Predicting 6-Year Mortality Risk in Patients With Type 2 Diabetes: Response to Wells et al.. <i>Diabetes Care</i> , 2009, 32, e60-e60.	4.3	1
28	Abstract MP36: Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis. <i>Hypertension</i> , 2020, 76, .	1.3	1
29	Career story: Medical Statistician. <i>Significance</i> , 2004, 1, 174-175.	0.3	0
30	Microvascular outcomes in type 2 diabetes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 580.	5.5	0